Matches in Nanopublications for { ?s ?p "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP788855.RAYTMHkO2DuJ4-ja2mvGie_lJxEOyJeDfEZjlGalG2dcY130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788855.RAYTMHkO2DuJ4-ja2mvGie_lJxEOyJeDfEZjlGalG2dcY130_provenance.
- assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP788854.RAnlAzLiBM9sJ0ufMk472mocpbyzIOBG7U1-P-ryxMVRg130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788854.RAnlAzLiBM9sJ0ufMk472mocpbyzIOBG7U1-P-ryxMVRg130_provenance.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_provenance.
- NP585309.RAOvOYbvD0wcYfbanSEzAYkKoc5WeC0A1q3hskKk7fT38130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP585309.RAOvOYbvD0wcYfbanSEzAYkKoc5WeC0A1q3hskKk7fT38130_provenance.
- NP788850.RA5NsrfOdK-EzM286LynwmE2XDenMu5dzXwVBxnZPumnw130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788850.RA5NsrfOdK-EzM286LynwmE2XDenMu5dzXwVBxnZPumnw130_provenance.
- NP962541.RA9KmvMY6Zh4ICFZHyqi8J00OlAeaHTDP3cFyxwIx3dxI130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962541.RA9KmvMY6Zh4ICFZHyqi8J00OlAeaHTDP3cFyxwIx3dxI130_provenance.